Back to Journals » Cancer Management and Research » Call For Papers
Cancer Management and Research
The following Article Collections/ Thematic Series are currently open for submissions:
Cancer Management and Research is pleased to announce an upcoming Article Collection dedicated to the transformative role of CAR-T therapy in the management of cancer.
Since the 2017 US FDA approval of the use of anti-CD19 CAR-T cell therapy for use against B-cell malignancies, CAR-T therapy has demonstrated significant clinical benefits in treating hematologic malignancies, showing clinical efficacy and durability even in patients who have been refractory to other treatments. Research is underway to develop and evaluate CAR-based therapies for application in solid tumors.
Despite the remarkable impact of CAR-T therapies, challenges remain, including antigen escape, limited persistence, and overcoming the immunosuppressive microenvironment. Further, life-threatening toxicities, the high costs of manufacturing, and the need for a well-trained workforce currently limit the widespread use of CAR-T for cancer treatment.
Given the impact and continued importance of CAR-T cell therapies in cancer treatment, Cancer Management & Research welcomes submissions of original research articles, reviews, and perspectives on CAR-T, including basic science, translational research, clinical efficacy, and real-world implementation.
This Article Collection is part of a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.
The deadline for submitting manuscripts is 1 April 2026. Please review the journal’s Aims and Scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code TFRFH when prompted during submission.
Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.
Cancer stem cells (CSCs) are a therapy-resistant subpopulation that drives tumor initiation, progression, metastasis, and recurrence. Their capacity for self-renewal, plasticity, and adaptation underpins resistance to chemotherapy, radiotherapy, and immunotherapy, making them a central obstacle to long-term therapeutic success. Eradicating CSCs is thus recognized as a critical goal in improving long-term patient survival.
However, CSC research and targeted therapy face numerous challenges. Currently, there is a lack of universally applicable CSC-specific biomarkers, making it difficult to precisely target CSCs without damaging normal stem cells. Furthermore, CSCs continuously interact with the tumor microenvironment, including hypoxic homeostasis, matrix support, and immune regulation; these external conditions further enhance CSC survival and drug resistance. Recent advances in single-cell omics, spatial omics, and artificial intelligence technologies have provided new tools for revealing the heterogeneity, metabolic characteristics, and regulatory networks of CSCs. Based on these technological innovations, new strategies such as metabolic inhibition, synthetic biology intervention, and immunotherapy are being studied to target CSCs, with the potential to overcome CSC-mediated therapeutic resistance.
This Article Collection aims to gather the latest research progress in the field of cancer stem cells and to facilitate exchange and discussion on key issues such as drug resistance mechanisms, biomarker discovery, and clinical translation. Selected high-quality contributions from the 2026 International Conference on New Models for Cancer Prevention and Treatment (NMCPT 2026, http://www.nmcpt.com/), together with externally submitted manuscripts, will be included. Both original research articles and authoritative reviews are welcome.
Topics of interest include, but are not limited to:
• Molecular Mechanisms & Biomarkers: Intrinsic and microenvironment-mediated resistance pathways; discovery and validation of CSC-associated biomarkers for diagnosis, prognosis, and treatment stratification.
• Tumor Ecosystem: The role of the tumor microenvironment (immune, stromal, metabolic) in sustaining CSCs and fostering therapeutic escape.
• Innovative Therapeutics: Novel strategies targeting CSC vulnerabilities, including small molecules, immunotherapies, epigenetic modulators, and rational combination therapies.
• Translational & Clinical Research: Preclinical validation in advanced models (e.g., patient-derived organoids, in vivo models); pilot and early-phase clinical trials of CSC-targeting agents; studies on minimal residual disease and recurrence.
Submitting authors are eligible for a 10% discount on the Article Publishing Charge. To apply this discount, enter the code B4C3A when prompted during submission.
Manuscript deadline:
31 October 2026
Guest Advisor:
Dr. Peixin Dong, Hokkaido University, Japan, [email protected]
Call For Papers
Editor-in-Chief: Professor Yong Teng
To see where Cancer Management and Research is indexed online view the Journal Metrics.
What is the advantage to you of publishing in Cancer Management and Research?
- It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove Medical Press website.
- Although Cancer Management and Research receives many papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
- The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Cancer Management and Research has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
- Many authors have found that our peer reviewers’ comments substantially add to their final papers.
To recover our editorial and production costs, and continue to provide our content at no cost to readers, we charge authors or their institution an article publishing charge.
PubMed
Cancer Management and Research is indexed on PubMed Central (title abbreviation Cancer Manag Res). All published papers in this journal are submitted to PubMed for indexing straight away.
Become a Favored Author and receive real benefits
If you haven't already joined the Dove Medical Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal coordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page.
Yours sincerely
Dr Yong Ten
Editor-in-Chief
Cancer Management and Research
Email: Editor-in-Chief
Updated 5 September 2025